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Abstract
Hepatitis C virus (HCV) infection becomes chronic in about 85 % of individuals as demonstrated
by the persistence of HCV. It is necesseray to treat acute hepatitis C infection. Interferon- is
generally used for the treatment of acute HCV infection.
Case presentation: A 55-year-old woman with a history of fatique and icter was diagnosed as
acute hepatitis C virus infection. She was treated with interferon- 2b 3 million unite sc three times
in a week and ribavirin 1000 mg daily for 6 months. Within 2 weeks of therapy, the alanine
aminotransferase (ALT) had became normal. At the end of the 3 months of therapy, HCV RNA
was negative and remained negative 6 months after the end of interferon treatment (sustained
response).
Conclusion: This report suggests that interferon- 2b and ribavirin may have a role in treatment
of acute hepatitis C virus infection.
Background
Interferon- 2b has been shown to be effective in the
treatment of acute Hepatitis C virus (HCV) infection [1].
We report a case of response to interferon- 2b and riba-
virin treatment for acute hepatitis C.
Case Presentation
This 55-year-old, previously healthy female presented in
December 2001 with a 2-week history of fatigue, and icter.
The laboratory tests revealed that high levels of alanine
aminotransferase (ALT), aspartate aminotransferase (AST)
and bilirubin. Therefore referred to our clinic.
There was no history of intravenous drug usage, blood
transfusions, tattoos, travel or alchol intake. Her medica-
tions included local corticosteroids for dermatologic le-
sions and oral antidiabetics for type 2 diabetes mellitus.
Her past medical history included a tonsillectomy for 40
years ago. There was no history of autoimmune disease.
On physical examination, the patient was icteric. There
was no asterixis, palmar erythema or spider nevi. The liver
was palpable. There was no splenomegaly, ascites or pe-
ripheral edema. Laboratory findings on admission includ-
ed an alanine aminotransferase (ALT) level of 1381 IU/l
and aspartate aminotransferase (AST) level of 1309 IU/l.
The other laboratory investigations demonstrated gamma
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glutamil transferase (GGT) 614 IU/l, blood glucose 419
mg/dl and total bilirubin 5.9 mg/dl. The WBC count was
4600 /l, platelets 214000 /l and hemoglobin 14 g/dl
with no evidence of hemolysis on Giemsa stain.
The patient was tested for positive for anti-HAV IgG and
negative for HBsAg, anti-HBc IgM, anti-HAV IgM, anti-
Delta, anti-HEV IgM and anti-HEV IgG. She was positive
for antibodies to HCV by third generation ELISA. HCV
RNA was detected in serum of patient by polymerase
chain reaction (PCR). The patient was negative for HBV-
DNA by PCR. HIV serology was negative.
The auto antibodies Antinuclear antibody (ANA), AntiD-
NA, anti-LKM-1, Antimitochondrial antibody (AMA),
Anti-smooth muscle (ASMA) were negative.
An abdominal computerized tomogram showed enlarged
liver and milimetric stones in fundus of bile bladder, no
evidence of biliary tree dilatation or obstruction.
A liver biopsy was performed to exclude chronic hepatitis
and this showed acute hepatitis. In the histologic picture
it was detected only liver tissue necrosis.
Treatment was started with interferon- 2b (Intron A,
Schering-Plough, USA) 3 million unite sc three times in a
week and ribavirin (Rebetol, Schering-Plough, USA) 1000
mg daily and continued for 6 months. Within 2 weeks of
therapy, the ALT had became normal. A complete re-
sponse with persistent normal ALT were observed. At the
end of the 3 months of therapy HCV RNA was negative
and remained negative 6 months after the end of interfer-
on treatment (sustained response). During the first dose
of interferon- 2b flu like symptoms were observed. Over-
all, interferon in combination with ribavirin was well tol-
erated and there were no laboratory abnormalities.
Discussion
Hepatitis C is a common cause of chronic liver disease but
is rarely associated with acute hepatitis. The majority of
patients have no clinical symptoms and jaundice in this
phase of acute viral hepatitis C. Clinical symptoms are not
difference with other types of hepatitis [2]. It is necesseray
to treat acute hepatitis C infection. HCV infection be-
comes chronic in about 85 % of individuals as demon-
strated by the persistence of HCV. HCV is the major cause
of cirrhosis and hepatocellular carcinoma [2]. Interferon-
 is effective in improving biochemical outcomes and
achieving sustained virologic clearance in patients with
acute hepatitis C [3]. If acute infection is confirmed (with
or without acute hepatitis), recent data suggest that early
treatment of acute HCV infection with interferon- may
be highly effective in preventing chronic HCV infection
[1]. These data underscore the importance of identifying
persons with acute HCV infection and promptly referring
them to experienced clinicians who can provide updated
counseling and treatment [4]. However the optimum
therapeutic regimen and duration of therapy for acute
HCV infection had not been defined. In most studies pa-
tients with acute HCV infection were treated with daily ap-
plication of interferon- [1,5,6]. There were only two case
reports and a small trial (nine cases) regarding the safety
and efficacy of using either interferon- or pegylated in-
terferon plus ribavirin in patients with acute HCV infec-
tion [4,7,8]. We achieved virologic and biochemical
response with interferon- 2b 3 million unite sc. three
times in a week and ribavirin daily. Also interferon- and
ribavirin treatment is standart treatment of chronic hepa-
titis C and more effective than interferon monotherapy
[9]. The addition of ribavirin to interferon raises the rate
of sustained response by a factor of two to three [5,10,11].
In our case the normalisation of ALT level was drastic in
two weeks and persistent response was obtained.
The optimal time to treat acute hepatitis after the onset of
infection is still unknown. In asymptomatic acute HCV in-
fection some groups recommend starting treatment im-
mediately, the therapy could be started immediately .
Others prefer to wait for an increase in transaminase levels
before starting treatment. The jury of the consensus con-
ference: treatment of hepatitis C which was organized ac-
cording to the methodological rules published by the
Agence Nationale d'Accreditation et d'Evaluation en Sante
(ANAES) could not advocate one or other of these ap-
proaches on the basis of current data [12]. In case of acute
icteric hepatitis C: the jury recommends not to treat im-
mediately, as spontaneous recovery may occur in approx-
imately 50% of cases. Detection of HCV RNA should be
done 12 weeks after the onset of jaundice, and treatment
should be started if the result is positive [12]. In a state of
marked endogenous immunological activation interfer-
on- might induce an uncontrolled immunological proc-
ess, which could increase hepatic activity [6]. Therapy
could be started more safely at the time when ALT activity
decreasing, like in our case.
In our case, liver biopsy was performed for differential di-
agnosis, but the biopsy is not recommended routinely in
acute HCV infection. The histologic finding is necessary
evaluated in continuity of clinical and serologic data. The
important for treatment of acute HCV infection is fact that
patients after passed viral hepatitis C (only anti-HCV pos-
itive) had proved chronic hepatitis by histologic examina-
tion of liver in future [1,2,6].
Conclusion
Early identification and treatment of acute HCV infection
is important. It was shown that interferon- treatment is
effective in the treatment of acute HCV infection. Interfer-Annals of Clinical Microbiology and Antimicrobials 2002, 1 http://www.ann-clinmicrob.com/content/1/1/3
Page 3 of 3
(page number not for citation purposes)
on- 2b + ribavirin combination is effective in our case for
the target goals of HCV RNA loss and prompt normaliza-
tion of aminotransferases. Prospective clinical trials with
large number of patients especially those using pegylated
interferon, with or without ribavirin, should be conducted
to choose optimum therapy for acute hepatitis C virus in-
fection, in these trials the role of prognostic factors such as
HCV genotype [13] and viral load [14] should be take in
account.
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